Genometrix Appoints Bruce Peacock to Board of Directors.

THE WOODLANDS, Texas--(BW HealthWire)--Oct. 30, 1998--Bruce A. Peacock has been appointed to the Board of Directors at Genometrix Incorporated, a biotech company that develops microarray devices and instrumentation for high throughput DNA/RNA analyses utilized by pharmaceutical, diagnostic and genomics companies. Mr. Peacock currently serves as Executive Vice President and Chief Operating Officer and as a member of the Board of Directors of Cephalon, Inc. He was previously Senior Vice President and Chief Financial Officer of Centocor, Inc.

"We are most honored to have Bruce join the Board and further strengthen our management team at this strategic time for Genometrix," quotes Mitch Eggers, CEO of Genometrix. In his financial management positions at Centocor and Cephalon, Bruce has orchestrated visionary financial strategies which have proven very successful. "Because of Bruce's financial acumen, we are strongly positioned to further skillfully develop the rapidly growing opportunities for cost-effective high throughput DNA microarray consumables and instrumentation," adds Eggers.

Genometrix Incorporated, located in The Woodlands, Texas, is a pioneer in the development of high throughput microarray technology for applied genomic, diagnostic and pharmaceutical development. Additional information can be obtained from the web at: www.genometrix.com.